Summary
This guide outlines the complexities and challenges associated with regulatory submissions in the pharmaceutical industry. It discusses the traditional approaches that have often led to inefficiencies and delays in the approval process. The document emphasizes the importance of well-organized and clearly written applications, as deficiencies can result in refusals to file (RTFs) and significant delays in drug approval. The guide details how continuous, end-to-end publishing approaches can streamline the submission process, reduce rework, and enhance collaboration among regulatory teams. It highlights the benefits of adopting a unified Regulatory Information Management (RIM) system, which allows teams to manage submissions on a single platform, thereby improving efficiency and reducing the risk of errors. The document also presents real-world examples of companies that have successfully implemented these continuous approaches, illustrating the potential for improved outcomes in regulatory submissions.
